Lilly psoriasis mAb successful in Phase 3 trial

Eli Lilly (LLY +0.5%) Bio-Medicines chief David Ricks says that "complete resolution of psoriasis is possible for significantly more people" after the company's therapy candidate, ixekizumab, achieves all primary and secondary endpoints in a 3,866-patient Phase 3 clinical trial comparing it to placebo and Amgen's (AMGN -0.1%Enbrel (etanercept).

Patients receiving both dosing regimens of ixekizumab (80 mg every two or four weeks) had significantly greater levels of skin clearance than the control group or the etanercept cohort. Between 78% and 90% of the test group achieved at least a 75% reduction in PASI score at 12 weeks. Also, 31% to 41% achieved PASI 100 (clear skin) at week 12 compared to 5% - 7% in the etanercept group.

Lilly plans to submit its marketing application to regulators in 1H 2015.

From other sites
Comments (1)
  • Jon Goldhilll
    , contributor
    Comments (6) | Send Message
    Interesting data - efficacy is nominally better than recent secukinumab data with fewer injections. Speed of response data will be important as well as the q12w dosing regimen being investigated by Lilly - see our analysis by searching under:


    UpdatesPlus-Psoriasis - Lilly reports impressive Phase 3 data for ixekizumab
    21 Aug 2014, 12:39 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs